Progress in the therapy of small cell lung cancer

Simon, M.; Argiris, Athanassios; Murren, John R.

doi:10.1016/s1040-8428(03)00118-5

Cited by 75 publications

(63 citation statements)

References 94 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Small cell lung cancer (SCLC) accounts for approximately 13% of all lung cancer cases (1,2). Although chemotherapy results in initially high response rates, disease recurrence is the most probable outcome and consequently, mortality rates are high.…”

mentioning

confidence: 99%

Phase II Study of Everolimus (RAD001) in Previously Treated Small Cell Lung Cancer

Tarhini

Kotsakis

Gooding

et al. 2010

Clinical Cancer Research

Self Cite

113

View full text Add to dashboard Cite

Purpose: Mammalian target of rapamycin (mTOR) is a promising target in small cell lung cancer (SCLC). We designed a phase II study of everolimus, an mTOR inhibitor, in previously treated, relapsed SCLC. Experimental Design: Patients were treated with everolimus 10 mg orally daily until disease progression. The primary endpoint was disease control rate (DCR) at 6 weeks. PI3K/Akt signaling pathway biomarkers were evaluated on baseline tumor tissue. Results: A total of 40 patients were treated: 23 had 1 prior regimen/sensitive relapse, 4 had 1 prior regimen/refractory, and 13 had 2 prior regimens. Twenty-eight patients received 2 or more cycles of everolimus, 7 received 1 cycle, and 5 did not complete the first cycle. Best response in 35 evaluable patients: 1 (3%) partial response (in sensitive relapse), 8 (23%) stable disease, and 26 (74%) progression; DCR at 6 weeks was 26% (95% CI = 11–40). Median survival was 6.7 months and median time to progression was 1.3 months. Grade 3 toxicities included thrombocytopenia (n = 2), neutropenia (n = 2), infection (n = 2), pneumonitis (n = 1), fatigue (n = 1), elevated transaminases (n = 1), diarrhea (n = 2), and acute renal failure (n = 1). High phosphorylated AKT expression was modestly associated with overall survival (HR = 2.07; 95% CI = 0.97–4.43). Baseline S6 kinase protein expression was significantly higher in patients with disease control versus patients with progression (P = 0.0093). Conclusions: Everolimus was well tolerated but had limited single-agent antitumor activity in unselected previously treated patients with relapsed SCLC. Further evaluation in combination regimens for patients with sensitive relapse may be considered. Clin Cancer Res; 16(23); 5900–7. ©2010 AACR.

show abstract

mentioning

confidence: 99%

Phase II Study of Everolimus (RAD001) in Previously Treated Small Cell Lung Cancer

Tarhini

Kotsakis

Gooding

et al. 2010

Clinical Cancer Research

Self Cite

113

View full text Add to dashboard Cite

show abstract

“…When compared to non-small cell lung cancer, SCLC generally has a more rapid doubling time, a higher growth fraction and earlier development of widespread metastases (15). Most patients with SCLC present with hematogenous metastases, while only about one third of patients present with limited disease confined to the chest (16). Approximately two thirds of patients present with overt hematogenous metastases, which commonly involve the contralateral lung, liver, adrenal glands, brain, bones, and bone marrow (15).…”

Section: Figure 3: Cd56 Positivity In Tumoral Cells (Cd56x400)mentioning

confidence: 99%

“…Approximately two thirds of patients present with overt hematogenous metastases, which commonly involve the contralateral lung, liver, adrenal glands, brain, bones, and bone marrow (15). In patients with limited-stage disease, response rates of 70% to 90% are expected after treatment with cisplatin and etoposide plus thoracic radiotherapy, while in the extensive-stage disease, response rates of 60% to 70% can be achieved with combination chemotherapy alone (16). Unfortunately, median survival rates are only 14 to 20 months and 9 to 11 months for patients with limited-stage and extensive-stage disease, respectively (17).…”

Section: Figure 3: Cd56 Positivity In Tumoral Cells (Cd56x400)mentioning

confidence: 99%

Small-cell lung cancer metastases in breast

Demirci¹,

Erdoğan²,

Demırağ³

et al. 2014

Respir Case Rep

View full text Add to dashboard Cite

Although primary breast tumors are quite common, metastatic involvement of all breast masses are rare and account for about 1-5% of cases. A 56-year-old female patient was admitted to our clinic in July 2009 with complaints of shortness of breath. Thoracic computed tomography (CT) scan showed a mass in the left hilar region. Endobronchial lesion was determined by fiberoptic bronchoscopy and the biopsy was evaluated as small cell lung carcinoma. The patient was followed-up after 4 cycles of etoposide + cisplatin chemotherapy. In the follow-up period, due to an increase in shortness of breath the patient was admitted to our clinic again in April 2010. A 4x3x3 cm sized mass in the right upper quadrant of breast lesions obtained for re-staging positron emission tomography (PET-CT) showed intense FDG uptake increase. Needle biopsy of the breast was evaluated as a result of metastasis of small cell lung carcinoma. The patient recieved second-line VAC chemotherapy in April 2010. This case of small-cell lung cancer and breast metastases is presented because of its rarity. Key words: Breast, metastasis, small cell lung carcinoma.Primer meme tümörleri yaygın olmasına rağmen memenin metastatik tutulumu nadirdir ve yaklaşık %1-5 oranında görülür. Elli altı yaşında kadın hasta Temmuz 2009'da nefes darlığı yakınması ile kliniğimize başvurdu. Toraks bilgisayarlı tomografisinde (BT) sol hiler kitle mevcuttu. Fiberoptik bronkoskopi ile saptanan endobronşiyal lezyondan alınan biyopsi sonucu küçük hücreli akciğer karsinomu (KHAK) olarak geldi. Hastaya 4 kür etoposid sisplatin kemoterapisi verildi ve sonrasında takibe alındı. Nisan 2010'da nefes darlığında artış yakınması ile tekrar kliniğimize kabul edildi. Yeniden evreleme amaçlı çekilen PET-BT'de sağ meme dış kadranda 4x3x3 cm ebadında SUVmax 13,29 olan artmış FGD tutulumu raporlandı. Memedeki lezyondan alınan biyopsi sonucu KHAK metastazı şeklinde değerlendi-rildi. Hastaya 2. basamak VAC (vincristin, adriyamisin, siklofosfamid) kemoterapisi başlandı. KHAK'nin memeye metastazı nadir olması nedeni ile sunuldu.Anahtar Sözcükler: Meme, metastaz, küçük hücreli akciğer kanseri.

show abstract

“…Practically all affected patients are treated with chemotherapy, either alone or in combination with a local therapy, such as radiation therapy. Although SCLC is one of the most chemo-sensitive solid tumors (3), recurrences occur in the majority of patients, particularly in the first year (4).…”

Section: Introductionmentioning

confidence: 99%

Association between serum tumor markers and metabolic tumor volume or total lesion glycolysis in patients with recurrent small cell lung cancer

Shi

Meng

et al. 2015

Oncology Letters

View full text Add to dashboard Cite

Abstract. The aim of the present study was to investigate the association between serum tumor markers and the metabolic tumor volume (MTV) or total lesion glycolysis (TLG), as determined by fluorine-18 fluorodeoxyglucose ( 18 F-FDG) positron emission tomography-computed tomography (PET/CT) in patients with recurrent small cell lung cancer (SCLC). Data from 21 patients with recurrent SCLC were collected. The levels of neuron-specific enolase (NSE), carcinoembryonic antigen (CEA) and cytokeratin 19 fragment 21-1 were measured at the time of the 18 F-FDG PET/CT examination. The MTV and TLG of all lesions were calculated. Pearson correlation analyses were used to estimate the correlations between NSE level and PET findings. Pearson correlation analyses showed that NSE was the only tumor marker to have a strong correlation with MTV or TLG (r=0.787, P<0.001; r=0.866, P<0.001, respectively). In patients with a normal NSE level, no correlation was found between NSE and MTV or TLG (r=0.018, P=0.958; r=-0.003, P=0.92, respectively), but a significant correlation was found in patients with an abnormal NSE level (r=0.789, P<0.01; r=0.872, P=0.01, respectively). Therefore, TLG and MTV may serve as sensitive markers of tumor burden in patients with recurrent SCLC, with TLG showing greater sensitivity. In patients with an abnormal NSE level, a higher NSE level indicates greater MTV and TLG.

show abstract

Progress in the therapy of small cell lung cancer

Cited by 75 publications

References 94 publications

Phase II Study of Everolimus (RAD001) in Previously Treated Small Cell Lung Cancer

Phase II Study of Everolimus (RAD001) in Previously Treated Small Cell Lung Cancer

Small-cell lung cancer metastases in breast

Association between serum tumor markers and metabolic tumor volume or total lesion glycolysis in patients with recurrent small cell lung cancer

Contact Info

Product

Resources

About